Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab

Motzer, 2020, NCCN guidelines insights: kidney cancer, version 1.2021, J Natl Compr Canc Netw, 18, 1160, 10.6004/jnccn.2020.0043 Flippot, 2018, Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma, Drugs, 78, 1443, 10.1007/s40265-018-0970-y Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060 Giannone, 2020, Immuno-metabolism and microenvironment in cancer: key players for immunotherapy, Int J Mol Sci, 21, 4411, 10.3390/ijms21124414 Kim, 2021, A systematic review and meta-analysis of the significance of body mass index on kidney cancer outcomes, J Urol, 205, 346, 10.1097/JU.0000000000001377 Steffens, 2013, Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study, Int J Urol, 20, 585, 10.1111/iju.12000 Choi, 2013, Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and metaanalysis, Int J Cancer, 132, 625, 10.1002/ijc.27639 Albiges, 2016, Body mass index and metastatic renal cell carcinoma: clinical and biological correlations, Journal of Clinical Oncology, 34, 3655, 10.1200/JCO.2016.66.7311 Sanchez, 2020, Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study, Lancet Oncol, 21, 283, 10.1016/S1470-2045(19)30797-1 Lalani, 2021, Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma, JAMA Oncology, 7, 773, 10.1001/jamaoncol.2021.0019 Boi, 2020, Obesity diminishes response to PD-1-based immunotherapies in renal cancer, JITC, 8 De Giorgi, 2019, Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab, Clin. Cancer Res., 25, 3839, 10.1158/1078-0432.CCR-18-3661 Bergerot, 2019, Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma, Kidney Cancer, 3, 63, 10.3233/KCA-180047 Brown, 2018, The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers, J Cachexia Sarcopenia Muscle, 9, 1200, 10.1002/jcsm.12379 Tolonen, 2021, Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: a review, Eur J Radiol, 145, 10.1016/j.ejrad.2021.109943 Heymsfield, 1997, Human body composition: advances in models and methods, Annu Rev Nutr, 17, 527, 10.1146/annurev.nutr.17.1.527 Vrieling, 2018, Body composition in relation to clinical outcomes in renal cell cancer: a systematic review and meta-analysis, Eur Urol Focus, 4, 420, 10.1016/j.euf.2016.11.009 Prado, 2016, Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact, Proc Nutr Soc, 75, 188, 10.1017/S0029665115004279 Kamarajah, 2019, Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis, Gastric Cancer, 22, 10, 10.1007/s10120-018-0882-2 Shachar, 2016, Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review, Eur J Cancer, 57, 58, 10.1016/j.ejca.2015.12.030 Ged, 2022, Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade, Clin Cancer Res, 28, 5180, 10.1158/1078-0432.CCR-22-1389 Martini, 2021, Body composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors, Front Oncol, 11, 10.3389/fonc.2021.707050 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Cespedes Feliciano, 2020, Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients, J Cachexia Sarcopenia Muscle, 11, 1258, 10.1002/jcsm.12573 Popuri, 2016, Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle, IEEE Trans Med Imaging, 35, 512, 10.1109/TMI.2015.2479252 Dabiri, 2020, Deep learning method for localization and segmentation of abdominal CT, Comput Med Imaging Graph, 85, 10.1016/j.compmedimag.2020.101776 Fearon, 2011, Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, 12, 489, 10.1016/S1470-2045(10)70218-7 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 2021 Antoun, 2010, Association of skeletal muscle wasting with treatment with sorafenib in patients with advnaced renal cell carcinoma: results from a placebo-controlled study, J Clin Oncol, 28, 1054, 10.1200/JCO.2009.24.9730 Gu, 2017, Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients, Sci Rep, 7, 7587, 10.1038/s41598-017-07955-6 Rini, 2022, Long- term outcomes with nivolumab plus ipilimumab versus sunitinib in first- line treatment of patients with advanced sarcomatoid renal cell carcinoma, J ImmunoTher Cancer, 10, 10.1136/jitc-2022-005445 Caan, 2018, The importance of body composition in explaining the overweight paradox in cancer-counterpoint, Cancer Res, 78, 1906, 10.1158/0008-5472.CAN-17-3287 Cespedes Feliciano, 2018, The obesity paradox in cancer: how important is muscle?, Annu Rev Nutr, 38, 357, 10.1146/annurev-nutr-082117-051723 Lee, 2019, The obesity paradox in cancer: epidemiologic insights and perspectives, Curr Nutr Rep, 8, 175, 10.1007/s13668-019-00280-6